WO2016114677A1 - Manufacture and use of hyperimmune egg pc2 - Google Patents
Manufacture and use of hyperimmune egg pc2 Download PDFInfo
- Publication number
- WO2016114677A1 WO2016114677A1 PCT/RO2015/000019 RO2015000019W WO2016114677A1 WO 2016114677 A1 WO2016114677 A1 WO 2016114677A1 RO 2015000019 W RO2015000019 W RO 2015000019W WO 2016114677 A1 WO2016114677 A1 WO 2016114677A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- antigen
- egg
- igy
- cell
- Prior art date
Links
- 230000000521 hyperimmunizing effect Effects 0.000 title claims abstract description 56
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 19
- 239000000427 antigen Substances 0.000 claims abstract description 83
- 108091007433 antigens Proteins 0.000 claims abstract description 82
- 102000036639 antigens Human genes 0.000 claims abstract description 82
- 241000287828 Gallus gallus Species 0.000 claims abstract description 32
- 235000013330 chicken meat Nutrition 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 230000001580 bacterial effect Effects 0.000 claims abstract description 21
- 241000894006 Bacteria Species 0.000 claims abstract description 19
- 230000003053 immunization Effects 0.000 claims abstract description 13
- 238000002649 immunization Methods 0.000 claims abstract description 13
- 241000894007 species Species 0.000 claims abstract description 10
- 241000700605 Viruses Species 0.000 claims abstract description 9
- 241000233866 Fungi Species 0.000 claims abstract description 7
- 206010034133 Pathogen resistance Diseases 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 26
- 230000028993 immune response Effects 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 13
- 230000001900 immune effect Effects 0.000 claims description 8
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 230000000890 antigenic effect Effects 0.000 claims 1
- 244000000007 bacterial human pathogen Species 0.000 claims 1
- 244000000008 fungal human pathogen Species 0.000 claims 1
- 244000000009 viral human pathogen Species 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 10
- 244000052616 bacterial pathogen Species 0.000 abstract description 3
- 235000013601 eggs Nutrition 0.000 description 74
- 210000001744 T-lymphocyte Anatomy 0.000 description 50
- 210000000987 immune system Anatomy 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 40
- 230000032683 aging Effects 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 23
- 208000015181 infectious disease Diseases 0.000 description 20
- 238000002965 ELISA Methods 0.000 description 18
- 230000007423 decrease Effects 0.000 description 17
- 230000036039 immunity Effects 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 210000001541 thymus gland Anatomy 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 15
- 210000003719 b-lymphocyte Anatomy 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000036541 health Effects 0.000 description 12
- 208000023275 Autoimmune disease Diseases 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 206010042674 Swelling Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 230000008961 swelling Effects 0.000 description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 10
- 210000002969 egg yolk Anatomy 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 241000725303 Human immunodeficiency virus Species 0.000 description 8
- 102000000588 Interleukin-2 Human genes 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 238000004108 freeze drying Methods 0.000 description 7
- 210000003071 memory t lymphocyte Anatomy 0.000 description 7
- 210000000822 natural killer cell Anatomy 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000026683 transduction Effects 0.000 description 7
- 238000010361 transduction Methods 0.000 description 7
- 208000030507 AIDS Diseases 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 210000004296 naive t lymphocyte Anatomy 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229930003427 Vitamin E Natural products 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 235000019165 vitamin E Nutrition 0.000 description 5
- 229940046009 vitamin E Drugs 0.000 description 5
- 239000011709 vitamin E Substances 0.000 description 5
- 201000003883 Cystic fibrosis Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 208000002925 dental caries Diseases 0.000 description 4
- 230000001079 digestive effect Effects 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000271566 Aves Species 0.000 description 3
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000702670 Rotavirus Species 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940111782 egg extract Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002992 thymic effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 208000002064 Dental Plaque Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010039438 Salmonella Infections Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000009109 curative therapy Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000003870 intestinal permeability Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 229960000380 propiolactone Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 206010039447 salmonellosis Diseases 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000006397 Ephrin-B1 Human genes 0.000 description 1
- 108010044099 Ephrin-B1 Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010017918 Gastroenteritis viral Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 206010067470 Rotavirus infection Diseases 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010071061 Small intestinal bacterial overgrowth Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000010641 Tooth disease Diseases 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000002303 anti-venom Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- HFNQLYDPNAZRCH-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O.OC(O)=O HFNQLYDPNAZRCH-UHFFFAOYSA-N 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000020974 cholesterol intake Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100001102 clostridial toxin Toxicity 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000007166 healthy aging Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000007380 inflammaging Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000002976 pectoralis muscle Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000007142 small intestinal bacterial overgrowth Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229940083538 smallpox vaccine Drugs 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 210000001534 vitelline membrane Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/087—Herpes simplex virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1235—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Salmonella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1242—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
Definitions
- Eggs today can be customized so as to provide various types of immunity by consuming them. 24 distinct organisms have been used for the immunization of a single chicken which can further produce eggs for the passive immunization for all these organisms 14 .
- SENIEUR protocol As an attempt to define the selection criteria for truly healthy old people for immune-gerontology studies.
- the SENIEUR protocol described four health stages based on clinical and laboratory data. In their effort to reduce their involvement in other studies, they compared the phenomena noticed in the natural healthy aging processes with the phenomena attributable to age-related diseases. Using the SENIEUR protocol, a few recent studies have contradicted many hypotheses on the immune system aging process. The following paragraphs present some of these recent immune- gerontology findings.
- T-cells are eliminated from the thymus before full aging, but thymic regression may keep T-cell population.
- These T-cells can induce B cells to produce autoantibodies against own antigens. This theory seems to be supported by studies on mice proving that transplanting a thymus from a fetus to elders with autoimmune disease may recover functions and treat the autoimmune disease.
- Apoptosis programmed cell death, consisting of chromosome condensation, degraded DNA and destruction of killer cells.
Abstract
This invention refers to the manufacturing method of the hyperimmune egg-PC2 consisting of preparation of antigens and immunization of laying chickens with a mixture of antigens prepared from human- and animal-pathogenic germs. This invention refers to the composition of antigens prepared from a mixture of antibiotic-resistant strains from a single bacterial species and from a mixture of various species of bacteria, viruses and fungi, all representing a stimulus administered in each chicken.
Description
MANUFACTURE AND USE OF HYPERIMMUNE EGG PC2
Inventors:
Patra§cu Ionel Victor, Chiurciu Viorica, Chiurciu Constantin,
Topilescu Georgiana and Mihai Iuliana
Technical field
Medicine, immunology, polyclonal antibodies, preventive and curative treatments by passive immunization, immunological health support of over 60 years old patients and immunosuppressive patients.
This invention describes a manufacturing method of the polyvalent hyperimmune egg IMU OINSTANT. This invention is directly related to the manufacturing method of the complex, highly purified antigen from the mixture of various antibiotic-resistant bacterial strains or standard from various bacterial species. This invention is directly related to the manufacturing method of the antigen by mixture of inactivated bacterial strains, yeasts and viruses with a special adjuvant QS21.
Description of invention:
Description of the stage of technique including references
During 1996 Prof. Dr. Roy Walford (1) determined that the biological decline of the adult is based on the immunological aging of the organism, called immunosensescence. Dr. Walford explains at length that the immune system decline is the major cause of systemic aging, including the increased risk of cancer, infections and swelling1.
Researchers' concern for finding various solutions to cure diseases often starts with the study of the human immune system. Without this defense "invisible wall" provided by a strong immune system, the man is susceptible of almost any possible disease, from pneumonia to arthritis and diabetes2"4. Even cancer or cardiovascular di seases take advantage of the weakness or overactivity of normal immune functions 5·6.
Infections and cancer occur when the immune system loses its normal surveillance or intensive control capacity7. Cancer patients are extremely vulnerable to infections because both the disease and treatments keep on attenuating the immune system. On the other side, autoimmune diseases occur when the natural restrictions of the immune system reactivity decrease, allowing instead an uncontrolled inflammatory response which, in its turn, may increase the risk of cancer8'9.
The good news is that by protecting or even stopping the aging of the immune system we can substantially delay the pathological impact of aging itself10'1 1. Scientists are constantly looking for new immunity enhancement methods via food supplements, diets, physical exercise, rest and of course through expensive medication applied by the pharmaceutical industry.
Scientists have discovered a very interesting way of providing a natural immunological support using immune-protective proteins from chicken eggs. This discovery engages to substantially increase immunity for just a small part of the price of medication12. This is good news for each of us as we get older and great news at the same time for all people whose immune system is weak, such as cancer or HIV/AIDS patients.
Recent studies on the biological support of human body during aging using the hyperimmune egg have demonstrated that immunoglobulins react particularly with the pathogenic germs they were produced for in the organism of immunized chickens. This activity reflects upon the intestinal mucosa where it improves cell membrane functions also generating a biological comfort by neutralizing the toxins in the digestive contents. Hyperimmune egg consumption protects and even stops immune system aging and substantially delays the pathological impact of aging itself 10;1 ! . Hyperimmune egg consumption allows the substantial enhancement of immunity for just a small part of the price of medication 12.
In the last 25 years, chickens have been more and more used instead of mammals for antibody production. The biggest advantage is the fact that antibodies are collected from the egg
and not from the serum. At the same time, the amount of antibodies produced by a laying chicken is larger than that produced by a mammal of the same size. Mammalian immunoglobulin purification is a time-consuming and expensive procedure. Nowadays chickens are considered a cheap and convenient source of antibodies. The amount of immunoglobulin obtained from one egg is equal to that prepared from 300 ml rabbit blood.
Eggs today can be customized so as to provide various types of immunity by consuming them. 24 distinct organisms have been used for the immunization of a single chicken which can further produce eggs for the passive immunization for all these organisms14.
Cholesterol control. Atherosclerosis is another symptom of immunosenescence. The increasing lack of control of swelling facilitates the formation of clogged arteries within a process the Americans call "inflamm-aging"18 19. The US Army Research Institute of Environmental Medicine has become interested in this process due to the extremely large number of soldiers with a high cholesterol level and decided to study the potential of hyperimmune egg extract in decreasing the cardiovascular risk20.
It was discovered that the cholesterol of soldiers who had drunk a solution of hyperimmune egg powder was stable compared to the placebo-treated control group, whose cholesterol level kept increasing20. This finding contradicts the general preconceptions that the egg is a cause of cholesterol increase.
This 26-week study included army staff with cholesterol over 180 mg/dl20. All subjects had the same physical characteristics and participated during the study in a food educational program to reduce fat and cholesterol intake. Until the end of the study the total cholesterol level of the control group increased while the subjects receiving the supplement revealed no change. Similarly, placebo subjects had an increased total cholesterol-to-HDL ratio, while no change was noticed in the supplemented group. These findings proved that the hyperimmune egg could be beneficial in changing the serous lipoprotein level, reducing cardiovascular disease risk20
Fight against swelling and arthritis. During the immune decline, the human body can face increased immune system reactivity as excessive swelling. This paradox appears due to the fact that the immune system includes strong defense mechanisms which normally control swelling once the real threat disappeared. If the immunological functions are damaged, the organism becomes vulnerable to excessive swelling18.
Once with aging, the immune-regulatory function decreases, increasing at the same time the risk of chronic autoimmune diseases such as lupus or rheumatoid arthritis. Normally, these diseases are difficult to cure but the hyperimmune egg proved to be considerably successful in reducing this type of swelling, on animals14,21"23.
Research conducted on human subjects at Weill Cornell Graduate School of Medical Sciences demonstrated the efficacy of hyperimmune egg therapy in patients with various kinds of arthritis24. There was a significant improvement of patients after starting supplementation including rheumatoid arthritis patients. This improvement lasted 30 days after the end of treatment. Researchers reached to the conclusion that hyperimmune egg products can reduce the intestinal load with organisms tending to cross-react with the human tissue during the autoimmune response24.
Oral cavity health. Immunosenescence brings along many negative changes inside the oral cavity particularly in teeth and gums which can hide pathogenic germs and swellings resulting eventually in chronic conditions such as cardiovascular diseases25"26. The dental plaque is a real bacteria and inflammatory molecule biofilm increasing the risk of cavity or gum swelling (gingivitis).
The hyperimmune egg extract can reduce the volume of microorganisms in the dental plaque decreasing mouth swelling27. A group of animals receiving hyperimmune egg against tooth decay bacteria had a decreased number of tooth decays than the control group 28"29. Hyperimmune egg throat wash was also successful in people to reduce bacterial diseases; it seems that the extract remains active and present in the mouth at least overnight, providing long-term protection30"32. Fighting against teeth and gum diseases also involved tooth pastes and chewing gums containing hyperimmune egg extracts33.
Gastrointestinal infections. Immunosenescence is involved in the gastrointestinal tract (Gl), which is considered one of the biggest organs creating the bond between human body and environment. During normal immunological protection, the GI tract allows the selective passage of nutrients and beneficial fluids excluding millions of harmful organisms. The normal GI tract produces beneficial IgA antibodies which cover and isolate bacteria. The GI tract also contains a series of immune system-specific guard cells which recognize and act instantly against threats.
Once with aging, all these GI functions decrease, making us vulnerable not only to digestive infections or diarrhea, but also to other malign diseases such as colon cancer, one of the most severe diseases of elders34"36. The bacterial superinfection extending to the small intestine is a major concern, often misdiagnosed in elders37.
The most common viral infections of the GI tract are unresponsive to antibiotics and even exacerbated by them38 39. A more efficient method is needed which does not require chemical killing of organisms, but inactivating and preventing them from spreading. The hyperimmune egg specifically provides this approach. The most common toxic microorganisms in people are Salmonella and E. coli bacteria and rotavirus. Studies on animals revealed almost 100% efficacy of hyperimmune egg preparations against these bacteria, even if treatment is carried out post infection40 44. For instance, mice were protected against rotavirus and Salmonella infections by oral administration of hyperimmune egg44"46. The animals used in the trial also received a partial
protection against strains other than those chickens had been immunized against at the beginning42"44! Of equal importance for public health specialists, the subjects receiving hyperimmune egg have almost zero excretion of viruses or bacteria compared to the extremely high level of transmission of these microorganisms in control animals47"50. The hyperimmune egg is also effective against already-onset infections, with up to 84% healing rate and reducing germ discharge in the stool.
Another interesting study was conducted on human subjects by worldwide expert S.A. Sarker from the International Diarrheal Disease Research Center. He proved that the hyperimmune egg shown similar efficacy with milk-based products concerning rotavirus treatment in children 17"51.
It is obvious that the hyperimmune egg gas a prevention and treatment potential against extremely dangerous infections of not only the digestive tube, as we shall further demonstrate.
Other antibacterial effects. Of course, the immunosenescence-induced poor immunity makes us vulnerable to a great variety of bacterial infections outside the gastrointestinal tract as well. The hyperimmune egg extracts have a high potential against such infections.
Cystic fibrosis (CF) patients are particularly exposed to Pseudomonas aeruginosa (PA) colonization in the lungs, an organism which grows in its own secretion. PA infections are in fact the major cause of death and paralysis in CF patients52. Among the cystic fibrosis patients who performed throat wash with a hyperimmune egg obtained from PA-immunized chickens, none was chronically colonized with this organism while 24% of the control subjects were colonized52.
The hyperimmune egg proved its efficacy against other respiratory infections as well. A group of patients with bacteria-induced throat aches used a throat spray containing hyperimmune egg and experienced a dramatic diminution of symptoms, compared to placebo patients53.
HIV/AIDS people. Many ways, the human immunodeficiency virus (HIV) infection resembles the accelerated immunosenescence by low immunity and characteristic excessive swelling59. A study on HIV/AIDS people demonstrated the remarkable benefits associated with hyperimmune egg intake60. The supplemented subjects experienced overall improvement of living, including less anorexia, abdominal pains, diarrhea, short-term memory loss, dizziness, headaches and insomnia. Breathing pains and difficulties were also reduced and all subjects significantly gained weight until the end of the 8 weeks study. The swelling markers decreased significantly and the number of the most important lymphocyte CD4, an immune function indicator, improved in 20% of patients.
This is a major finding, considering the immune system suppression degree usually seen in HIV/AIDS patients and the outrageous expenses of the standard treatment. It is a real progress to be able to prevent so much sufferance through a cheap and easy to administer egg.
Immune support in cancer patients. Immunosenescence is an important factor for cancer occurrence, because in this case, the high level of normal immune system surveillance against potential malign diseases is reduced. At the same time, cancer as much as HIV/AIDS, brings along some kind of accelerated immunosenescence, with cancerous calls invading and weakening their unlucky hosts. Chemotherapy aggravates the situation, making cancer patients even more vulnerable to infections. The Gl is extremely impaired both by the disease and by chemotherapies, both increasing the intestinal permeability which eventually allows the occurrence of infections in the body61.
Surprisingly, various types of orally administered antibodies had a promising effect in improving cancer and chemotherapy symptoms in the GI tract62. A mixture of human IgA and IgG antibodies orally administered in patients with bone marrow transplant prevented the harmful increase of intestinal permeability noticed in placebo patients63.
Animal immunoglobulin (similar with the biologically active proteins from the hyperimmune egg extract) was able to reduce fungi colonization during oral administration in patients with bone marrow transplant64. These studies validated the use of hyperimmune egg to support digestive system immunity in immunosuppressive cancer patients and opened the door to new studies with even more dramatic results.
We live in an unfriendly world, surrounded by an environment full of microbes and toxins which can intensely impair our health or can cause us chronic pains and ailment. As we grow old, immunosenescence weakens our immune system making us vulnerable not only to infections but also to cancer or other autoimmune or inflammatory diseases. The medical biochemistry or pharmaceutical industry approaches not always succeed in healing, and they even may increase the risk of such diseases (as in the case of excessive antibiotic prescription resulting in the development of new organisms harmful for human health).
Nevertheless, the hyperimmune egg laid by the chicken is a natural reservoir of protective elements which can improve human health. Chickens immunized against disease-causing organisms lay eggs enriched with substances able to improve human health, both in the GI tract and other parts of the body. Gastrointestinal diseases and also infections and excessive swelling are real targets for hyperimmune egg supplementation. Moreover, hyperimmune egg supplements can improve the immunity of HIV/AIDS people and even proved to be able to support the immunity of cancer patients. There is no doubt: hyperimmune eggs are a unique approach for the protection of health and longevity.
The number of old people is in unprecedentedly permanent increase at present. Due to the recent state-of-the-art technology and better feed, people live longer than before, especially in the developed countries where lifespan doubled from 45 to 80, in 2000. A good health for old people requires medical scientific studies on aging. The immune system is one of the body functions
deeply impaired by aging. Research on aging must focus on the immunological aging phenomena in order for us to understand aging as a whole.
Many changes in old people are related to the innate immunity of those people as well as the immunity acquired during lifetime. The immune system impairment in elders is generally regarded as immunity deterioration called immunosenescence. Various immunological parameters are often reduced in elders and the ratio between innate and acquired immunity remains relatively similar throughout lifetime. Lately, the acknowledgment of the immune system role in elders has increased the number of publications in geriatric and gerontology science magazines. The magazine Immunity & Ageing was issued in 2004, being an "on-line" magazine with the purpose of publishing the large number of papers that did not have enough room in the printed publications.
Immunogerontology, the study of the immune system of elders, is a relatively new field, therefore no key information is yet available on this topic. The conclusions of studies on animals or tissue cultures and on humans were inconsistent, but these discrepancies shall probably be solved once more information is available. This situation is due to the fact that gerontologists did not use universally accepted definitions regarding the beginning of aging or when a person is considered old. Studies on aging involve a comparison between a young population and old population without trying to define who is old and who in young. Without a clear definition of these terms it is difficult to determine whether the immunological difference noticed in elders are the result of aging or age-related diseases. Many studies were exclusively focused on the fact that in order to live for 100 years, the old person should be exceptionally healthy. Even if this population is very limited, the conclusion of these studies helped deciding the basic paperwork for broader documentation on aged youth.
In 1984, a team of researchers developed the SENIEUR protocol as an attempt to define the selection criteria for truly healthy old people for immune-gerontology studies. The SENIEUR protocol described four health stages based on clinical and laboratory data. In their effort to reduce their involvement in other studies, they compared the phenomena noticed in the natural healthy aging processes with the phenomena attributable to age-related diseases. Using the SENIEUR protocol, a few recent studies have contradicted many hypotheses on the immune system aging process. The following paragraphs present some of these recent immune- gerontology findings.
It is well-documented that immunocompetence decline occurs once with aging or better said it is related to the age of people. In this case, the immune system starts losing some of its functions and can no longer respond fast or efficiently to stimuli. Age-related changes of the host:
^ in the immune system;
^ chemical changes and modification of proteins found on cells' surface; ^ impairment of the entire organism.
Studied separately, some of these changes seem strange, but when studied together they reveal to radically impair the overall health of the person. A major change encountered in the aged body is the involution of thymus. The thymus is an organ where T-cells maturate. T-cells are very important since they are a specialized lymphocyte population with various functions:
^ they kill bacteria;
^ they help other immune system cells.
The thymus is naturally atrophied once with aging. At the age of 60, the thymus is less than 5% compared to birth if we consider a lifespan of 120 years, when the thymus will be completely disappeared. T-cells are permanently produced throughout lifetime and thymus atrophy results in permanent decrease of T-cells during life. It is unknown why thymus deteriorates. It seems that it is an extremely low energetic organ required by the organism during the first stages of life. It does not have time to develop its own resistance against extraneous antigens. Once with the full development of the immune system, to protect the host from billions of antigens, keeping the thymus at energetic level is very difficult. For the organism it is better regarding evolution to decrease the amount of thymic tissue and use the energy that would support the thymus for other purposes. Since T-cells are very important for immunity, people who live longer always need a fresh T-cell reservoir that would protect the organism against new antigens and this slow but certain loss of the thymic tissue deeply impairs the immune system during aging. T-cell aging effects have various symptoms.
Many T-cell subpopulations are found in thymus and bloodstream, among which naive T- cells and memory T-cells. Naive T-cells are those T-cells that have never been exposed to any kind of extraneous antigen. These are activated and stimulated to identify extraneous antigens. Using memory T-cells, the immune system eliminates extraneous antigens from the body and stores the information in T-cell memory. T-cell memory enters a state of dormancy and is reactivated only by another exposure to the same antigen. A difference regarding naive and memory T-cell subpopulations was noticed between young and old persons. Newborns have more naive T-cells than memory T-cells. The ratio is backwards in adults because most naive T-cells transformed into memory T-cells by exposure to antigens. Old people no longer have naive T- cells due to the progressive deterioration of thymus once with aging and the population of naive
T-cells does not regenerate. Therefore the naive T-cell stock decreases and the aged immune system can no longer respond as well as in young people to new antigens.
Once with the decline of T-cell subpopulation, there are important changes on cell surface of all T-cells. The T-cell uses the T receptor protein found in the cell surface to bind to an antigen, communicating the stimulus inside the cell. Many molecules are involved in signal transduction. The antigen coupling and identification signal transmission processes pass through the cell membrane. The transduction signal is a chemical tandem reaction, each reaction depending on the case. Aged T-cells no longer recognize antigen CD 28, an important molecule for transduction signal and T-cell activation on the cell surface. In the absence of this protein, T-cells remain active without response to extraneous pathogenic stimuli. A T-cell transduction signal dysfunction clue is that cells have no response to extraneous pathogenic stimuli. Another clue is that the presence of antigen CD69 on cell surface is less in elders. T-cells produce the antigen CD69 only after binding to an antigen at the cell receptor. If the antigen binding signal is not transmitted inside the T-cell, the antigen CD69 will not appear on cell surface and this is a clue that no transduction signal is found in elders.
Another flaw in T-cell activity in elders is related to calcium decrease. Calcium is a vital element for many biochemical reactions including transduction signal. A calcium deficiency in T- cells stops the transduction signal by absence of enzymatic stimulation including of protein kinase C, MAPK and MEK, which need calcium for their own functions. Calcium decrease can inhibit the production of cytokines, proteins responsible for the coordination of antigen interaction and enhancement of the immune response.
A much studied cytokine is interleukin 2 (IL-2), a cytokine produced and secreted by T- cells, inducing cell proliferation and supporting the long-term increase of T-cells. Aged T-cells lose their capacity to produce and respond to IL-2. When exposed to an antigen, memory T-cells divide rapidly and proliferate in order to produce more cloned T-cells which, in their turn fight the antigen. This proliferation takes place with IL-2. If not enough cytokine IL-2 is produced or if T- cells cannot efficiently respond to IL-2, T-cell functions are much reduced. Changes were recorded for other cytokines such as cytokine 4, tumor necrosis Alfa factor and gamma-interferon, but it is yet unknown the impact of these changes on the aged immune system.
The age-related genetic impairment is found in T-cells. The in vitro study on human T- cells cultivated for a longer time have shown that division cycles become slower and then stop, right when cells grow in the presence of IL-2; the conclusion is that T-cells stop dividing and become too old to function. Many T-cell engineering-related issues are noticed once with cell growth decrease. The protein transcription factors (NF-kB and AP-1) which use DNA to create RNA during protein production processes seem to become unfit or inactive. Aging also contributes to this process decreasing T-cell response capacity by lack of activation of the genes required for T-cell stimulation. Aged T-cells are more sensitive to apoptosis or are programmed to die, by gradual loss of telomeres which are a problem for DNA damage-preventing chromosomes.
T-cell receptor gene rearrangement issues contribute to thymus regression by formation of less apoptosis-resistant cells. Therefore, T-cells seem to have a limited life and immunosensescence and are genetically programmed.
T-cell function decrease in elders impairs type B cell function since T-cells act together with B-cells to regulate the antibody production. T-cells induce B-cells to activate immunoglobulin genes, which in exchange creates the antibody range which is more limited in elders than T-cells range in youth. The production of immunoglobulin M, one of the five classes of antibodies, is particularly impaired. During infection, IgM is the first class of antibiotics to respond. The incapacity of elders to fight infections compared to young people can be related to the reduced IgM immune response. B cells aging rate decreases with age. B cells are produced in the bone marrow throughout life but their number decreases with age. With few aged B cells, the amount of antibodies produced as immune response to infection decreases.
Autoantibodies, the antibodies reacting against self antigens, are usually the distinctive symptoms of autoimmune disease. Still, the presence of autoantibodies is often correlated with age, even in healthy old people without autoimmune disease. Interleukin 10 (11-10) is a molecule which stimulates autoantibody production in autoimmune disease patients. 11-10 seems not to impair the health of old people. In exchange, autoantibody production in elders can be related to the above-mentioned functional modifications in T-cells. The production of small amounts of autoantibodies is normal during aging, the activity of which is unknown. A possibility would be that T-cell gene mutations which occur once with aging should create a T-cell subpopulation which recognizes the antigen of the host. Normally, these T-cells are eliminated from the thymus before full aging, but thymic regression may keep T-cell population. These T-cells can induce B cells to produce autoantibodies against own antigens. This theory seems to be supported by studies on mice proving that transplanting a thymus from a fetus to elders with autoimmune disease may recover functions and treat the autoimmune disease.
Other immune system cells are also impaired by aging. The activity of leukocytes, including macrophages, monocytes, neutrophils and eosinophils is reduced in elders. There is little information on the effects of aging on these types of cells.
Natural killer (NK) cells. These cells are created to secrete cytokines and kill other cells, and they have been studied very much. According to some data, NK cells decrease with age but this theory was based on studies on mice and was changed because it had been found out that their number in the human body was very little changed. The SENIEUR protocol was not taken into account in the beginning. The studies conducted with the SENIEUR protocol revealed that NK cell activation is very little changed in time, and a cross-study suggested that even if cytotoxic (cell-killing) functions of NK cells were maintained, the secretory activity of cytokines would be uncertain. While cytokines play an important role in tumor development and removal of infections, NK cell immunosenesecence may have an extensive effect on the immune system. Further studies on NK cells are necessary to settle these discrepancies.
What are the implications of all these changes in the aged immune system regarding elders' health? Two topics were studied to ensure health: vaccination and nutrition.
Old people are known for their bad tolerance to vaccination, unlike young people. Vaccination is done to educate the immune system against an infectious agent. Vaccine provide an non infectious substance containing the same antigen as pathogenic agents for the development of memory T-cell population and antibody-producing B cells so as to prevent further infections. Some vaccines like the avian smallpox vaccine need to be administered only once to provide lifetime immunity. Other vaccines, such as flu vaccine, need to be administered each year due to the existence of various virus strains and prevalence of a virus strain against others. Flu and pneumonia are two diseases which affect elders mostly.
For this reason, vaccines are a priority for medical assistance during aging. Nevertheless, the elders face particular vaccine-related modifications. The antibody response in elders is slower and weaker than in young people and T-cell subpopulations respond poorly to vaccination T-cell memory in elders does not react so quickly and for a long time like in young subjects. Many studies attempted to improve vaccines administered in old people. Studies are now conducted on a new type of vaccine which can release liposome or DNA (naked DNA) to develop a stronger immune response. There is an attempt of using new methods of vaccination among which the intranasal or oral spray to stimulate mucosal immunity.
Nutrition is particularly important for the immune response of seniors. At the same time, old people often face malnutrition. Less calories in food means slow aging and help maintaining a large number of naive T-cells and IL-2 level. Vitamin E and zinc are important nutrients for the appropriate functioning of the immune system. Long-term zinc deficiency in old people results in decreased cytokine production and therefore, low activity of T-cells. Vitamin E is a potential medicine in treating Alzheimer (CSA's Discovery Guide Series: Alzheimer's Disease de Fred Spangler). It was discovered at the same time that vitamin E supplements can enhance the immune system. In mice and people, a daily dose of vitamin E higher than the one recommended by the USA methodology, improves T-cell functions in the cell-mediated immunity. Vitamin E is also an antioxidant which can protect lymphocytes, brain and other tissues from the destructive free radicals.
We have seen that aging affects many components of the immune system which interacts with every organ in the body. A clear understanding of the immunological modifications resulting in aging is necessary for quality medical assistance of old people (65, 66).
Glossary
1. Adjuvant: a vaccine-incorporated non-reactive substance increasing the immune response to a vaccine. Adjuvants cannot stimulate the immune response without antigens.
2. Antibodies: proteins produced by B cells as response of an antigen's stimuli. Once recognized, B cell antigen produces the same type of antibodies which will bind only this antigen which has stimulated B cells.
3. Antigen: an extraneous substance binding with the antibodies or T-cell receptors which produce an immune response. Antigens can be proteins, carbohydrates, nucleic acids, hormones or other substances. The immune system usually responds against an extraneous antigen, but in case of autoimmune disease the immune system reacts against self-antigens released by the organism as if they were its own but extraneous antigens.
4. Apoptosis: programmed cell death, consisting of chromosome condensation, degraded DNA and destruction of killer cells.
5. Autoimmune disease: the immune system attacks its own organism and destroys tissues. The host's immune system makes errors on its self antigens against extraneous antigens and induces an immune response of tissues that have self antigens. Lupus, rheumatoid arthritis and multiple sclerosis are examples of autoimmune diseases in people.
6. B cells: a lymphocyte population maturing in bone marrow and producing antibodies. B cells can be found in bone marrow and bloodstream.
7. Antigens CD: proteins on the surface of lymphocytes serving as biochemical markers characteristic for a type of cells. CD can be used for differentiation (cluster differentiation) indicating the connection or maturation stage of lymphocytes. Molecules are approved to be called CD followed by a number (CD 28 or CD 69). Some antigens CD have known functions while others don't.
8. Cytokines: proteins synthesized by immune system cells reacting with the immune, nervous and endocrine systems. Cytokines can be immunostimulators or immunosuppressive. Cytokines include interleukins, interferon and some growth factors.
9. Immunocompetence: a quality or state of the immune system with appropriate functions.
10. Immunogerontology: study of the aging process of the immune system.
11. Immunoglobulin: another word for antibodies. Immunoglobulins are subdivided into 5 classes: IgM, IgA, IgE, IgD and IgG.
12. Immunosenescence: immune system aging.
13. Leukocytes: white blood cells. The leukocyte population consists of B cells, T-cells, monocytes, macrophages, basophiles, eosinophils, neutrophils and natural killer cells.
14. Liposome: fat vesicles containing a substance (drug or vaccine) intended for a special type of cell
15. Lymphocytes: a population of white blood cells, among which a cell subpopulation, B cells and natural killer cells.
16. Mucosal immunity: a part of the immune system associated with the mucosal tissues of the respiratory, gastrointestinal and urogenital tracts.
17. Natural killer cells: cells which attack and destroy virus-infected and tumor cells.
18. Signal transduction: a process in which a cell reacts to a stimulus from the environment by transmitting the information from the membrane surface inside the cell. The cell membrane has proteins/receptors for specific molecules. When molecules bind to a receptor, this produces a cascade of chemical reactions in the cell, involving enzymes, proteins and ions (especially calcium). Each reaction depends on the situation and if it is not part of it, it is lost and the transduction signal is interrupted.
19. T-cell receptor: a protein complex on the surface of T-cells binding with the antigen. Like antibodies, T-cell receptors are specific for certain antigens.
20. T-cells: a population of lymphocytes in the blood, maturing in the thymus. T- cells can be found in the thymus, lymph nodes and bloodstream. T-cells face many infections including the assistance of other cells of the immune system, killing extraneous pathogens or the infected cells even suppressing the immune response.
21. Telomere: special proteins to repeat DNA sequences at the end of the chromosome protecting chromosomes from degradation.
22. Thymus: an organ above the heart, where T-cells mature
23. Transcription factors: proteins helping RNA synthesis using a DNA template. Protein NF-kB and protein AP-1 are two very well known transcription factors.
References:
Effros RB. Roy Walford and the immunologic theory of aging. Immune Ageing. 2005 Apr 25; 2(1): 7.
Lindstrom TM, Robinson WH. Rheumatoid arthritis: a role for immunosenescence? Am. Geriatr Soc. 2010 Aug; 58(8) : 1565-75.
Zeitler P. Approach to the obese adolescent with new-onset diabetes. J Clin Endocrinol Metab. 201() Dec:95(12):5163-70.
Sannikova TE, Marchuk Gi, Romaniukha AA, lashin AI. Immune system senescence and mortality dynamics. Role of antigenic load. Adv Gerontol. 2003; 12:91-8.
Pawelec G, Derhovanes ian E, Larbi A. Immunosenescence and cancer. Crit Rev Oncol Hemalol. 2010 Aug; 75(2): 165-72.
Man DL, Topkara VK, Evans S, Barger PM. Innate immunity in the adult mammalian heart: for whom the cell tolls. Trans Am Clin Climatol Assoc. 2010:121:34-50; discussion 50-1.
Gupta S, Bi R, Su K, Yel L, Chiplunkar S, Gollapudi S. Characterization of naive, memory and effector CD8+ T cells: effect of age. Exp Gerontol. 2004 Apr; 39(4): 545-50.
Gupta S, Agrawal A, Agrawal S, Su H, Gollapudi S. A paradox of immunodeficiency and inflammation in human aging: lessons learned from, apoptosis. Immiin Ageing. 2006 May 19:3:5. Probst-Hensch NM. Chronic age-related diseases share risk factors: do they share
pathophysiological mechanisms and why does that matter? Swiss Med Wkly. 2010 Sep l;140:wl3072.
Pfister G, Savino W. Can the immune system still be efficient in the elderly? An immunological and immunoendpcrine therapeutic perspective. Neuroimmunomodulation. 2008; 15 (4-6): 351-64. Dorshkind K, Montecino-Rodriguez E, Signer RA. The ageing immune system: is it ever too old to become young again? Nat Rev Immunol. 2009 Jan;9(l):57-62.
Pawelec G, Barnett Y, Forsey R, el al. T cells and aging, January 2002 update. Front Biosci. 2002 May l; 7:dl056
Dias da Silva W, Tambourgi DV. IgY: a promising antibody for use in immunodiagnostic and in immunotherapy. Vet Immunol Immunopathol. 2010 Jun 15; 135(3-4): 173-80.
Dean KL. Hyperimmune eggs capture natural immune support. Altern Complemen Titer. June 2000:6(3): 1.18-24.
Cama VA, Sterling CR. Hyperimmune hens as a novel source of anti-Cryptosporidium antibodies suitable for passive immune trans fer. J Protozoal. 1991 Nov-Dec; 38(6) : 42S-43S.
Fujibayashi T, Nakamura M, Tominaga A, et al. Effects of IgY against Candida albicans and Candida spp. Adherence and biofilm formation. Jpn J Infect Dis. 2009 Sep:62(5):337-42.
17. Sarker SA, Casswall TH, Juneja LR. et al. Randomized, placebo-controlled, clinical trial of hyperimmunized chicken egg yolk immunoglobulin in children with rotavirus diarrhea. J Pediatr Gastroenterol Nutr. 200 Uan; 32(1): 19-25.
18. Franceschi C, Bonafe M. Valensin S, et al. Inflamm-aging. An evolutionary perspective on
immunosenescence. Ann N Y Acad Sci. 2000 Jun;908:244-54.
19. Candor e G Caruso C, Jirillo E. Magrone T, Vasto S. Low grade inflammation as a common pathogenetic denominator in age-related diseases: novel drug targets for anti-ageing strategies and successful ageing achyper immune eggvement. Curr Pharm Des. 2010; 16(6): 584-96.
20. Karge WH. Dehtca JP, Marchitelli LJ. et al. Pilot study on the effect of hyperimmune egg protein on elevated cholesterol levels and cardiovascular risk factors. J Med Food. 1999:2(2): 51-63.
Franceschi C, Bonafe M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence.
Ann N Y Acad Sci. 2000 Jun;9Q8: 244-54.
21. Miirosaki S, Yoshikai Y, Kuho C, et al. Influence of intake of skim milk from cows immunized with intestinal bacterial antigens on onset of renal disease i (NZB x NZW)F1 mice fed ad libitum or restricted in energy intake. J Nutr. 1991 Nov; 121 (11): 1.860-8.
22. Ormrod DJ, Miller TE. The an ti- inflammatory activity of a low molecular weight component derived from the milk of hyperimmunized cows. Agents Actions. 1991 Mar; 32(3-4): 160-6.
23. Ormrod DJ. Miller TE. Milk from hyperimmunized dairy cows as source of a novel biological
response modifier. Agents Actions. 1993:38 Spec No:C 146-9.
24. Greenblatt TIC, Adalsteinsson O, Kagen L. Administration to arthritis patients of a dietary supplement containing immune egg: An open-label pilot study. J Medicinal Food. 1998; 1(3): 171 -9.
25. Klosinska A, Nowacka M, Kopec G, et al. Periodontitis and the risk of cardiovascular diseases - review of epidemiological studies. Kardiol Pol. 2010 Aug; 68(8): 973-6.
26. Bodineau A, Folliguet M, Seguier S. Tissular senescence and modifications of oral ecosystem in the elderly: risk factors for mucosal pathologies. Curr Aging Sci. 2009 Jul; 2 (2): 109-20.
27. Hatta H, Tsuda K, Ozeki M, et al. Passive immunization against dental plaque formation in
humans: effect of a mouth rinse containing egg yolk antibodies (IgY) specific to Streptococcus mutans. Caries Res. 1997;31(4):268-74.
28. Otake S. Nishihara Y, Makimura M. el al. Protection of rats against dental caries by passive immunization with hen-egg-yolk antibody (IgY). J Dent Res. 1991 Mar; 70(3): 162-6.
29. Mitoma M, Oho T, Michibata K et al. Passive immunization with bovine milk containing
antibodies to a cell surface protein antigen-glucosyltransf rase fusion protein protects rats against dental caries. Infect Immun. 2002 May; 70(5): 2721-4.
30. Coriander D, Kollberg H. Larsson A. Retention of specific yolk IgY in the human oral cavity.
Bio Drugs. 2002; 16(6) : 433- 7.
31. Wang WH. Wang WJ, Zhang BX. Effect of IgY solution on dental plaque. Zhonghua Kou Qiang Yi Xue Za Zhi. 2003 Nov; 38(6): 417-9.
32. Zhou Z, Zhou R, Tang Z. Effects of topical application of immunoglobulin yolk on mutans streptococci in dental plaque. Hua Xi Kou Qiang Yi Xue Za Zhi. 2003 Aug; 2 J (4): 295-7.
33. Chi ZB, Gao YX, Pan Y, Zhang B, FengXP. The inhibitive effect of IgY toothpaste against oral Streptococcus mutans. Shanghai Kou Qiang YiXue. 2004 Aug; 13 (4) : 256-8.
Sarker SA, Casswall TIL June/a LR. et al. Randomized, placebo-controlled, clinical trial of
hyperimmiinized chicken egg yolk immunoglobulin in children with rotavirus diarrhea. J Pediatr Gastroenterol Nutr. 2001 Jan; 2(1): 19-25.
34. Kawanishi II. Recent progress in senescence-associated gut mucosal immunity. Dig Dis.
1993; 11(3): 157-72.
35. Schmucker DL, lleyworth MF, Owen RL, Daniels CK. Impact of aging on gastrointestinal
mucosal immunity. Dig Dis Sci. 1996 Jun; 41(6): 1183-93.
36. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010 Sep- Oct:60(5):277-300.
37. Riorda SM, Mclver CJ, Wakefield D, Bolin TD, Duncombe VM, Thomas MC. Small intestinal bacterial overgrowth in the symptomatic elderly. Am J Gastroenterol. 1997 Jan; 92(l):47-51.
38. Cutting WA. Mechanisms of diarrhoea and why they matter. Dialogue Diarrhoea. 1988
Dec; (35): 4-5.
39. Available at: http://digesHve.nidaTc.nih.gov/ddiseases/pubs/viralgastroenteritis/. Accessed January 28, 2011.
40. Ebina T. Prophylaxis of rotavirus gastroenteritis using immunoglobulin. Arch Virol Suppl.
1996;12:217-23.
41. Wiedemann V, Linckh E, Kuhlmann R, Schmidt P, Losch U. Chicken egg antibodies for
prophylaxis and therapy of infectious intestinal diseases. V. In vivo studies on protective effects against Escherichia coli diarrhea in pigs. Zentralhl Veterinarmed B. 1991 Jun;38(4):283-91.
42. O 'Farrelly C. Branton D, Wanke CA. Oral ingestion of egg yolk immunoglobulin from hens
immunized with an enterotoxigenic Escherichia coli strain prevents diarrhea in rabbits challenged with the same strain. Infect Immun. 1992 Jul;60(7):2593-7.
43. Marquardt RR, Jin LZ. Kim JW, Fang L, Frohlich AA, Baidoo SK. Passive protective effect of egg- yolk antibodies against enterotoxigenic Escherichia coli KS8+ infection in neonatal and early- weaned piglets. FEMS Immunol Med Microbiol. 1999 Apr;23(4):283-8.
44. Ebina T, Tsukada K, Umezii K, et al. Gastroenteritis in suckling mice caused by human rotavirus can be prevented with egg yolk immunoglobulin (IgY) and treated with a protein-bound polysaccharide preparation (PSK). Microbiol Immunol. 1990;34(7):617-29.
Yokoyama H, Umeda K, Peralta RC, et al. Oral passive immunization against experimental salmonellosis in mice using chicken egg yolk antibodies specific for Salmonella enteritidis and S. typhimurium. Vaccine. 1998 Feb; 16(4): 388-93.
Yokoyama H, Peralta RC. Umeda K, et al. Prevention of fatal salmonellosis in neonatal calves, using orally administered chicken egg yolk Salmonella-specific antibodies. Am J Vet Res. 1998 Apr;59(4): 416-20.
Hiraga C, Kodama Y, Sugiyama T, Lchikawa Y. Prevention of human rotavirus infection with chicken egg yolk immunoglobulins containing rotavirus antibody in cat. Kansenshogaku Zasshi. 1990 Jan;64(l): 118-23.
Kuroki M, Ikemori Y. Yokoyama 11 Peralta RC. lcatlo FC Jr, Kodama Y. Passive protection against bovine rotavirus-induced diarrhea in murine model by specific immunoglobulins from chicken egg yolk. Vet Microbiol. 1993 Oct; 37 (1-2): 135-46.
Imberechts H, Deprez P. Van Driessche E, Pohi P. Chicken egg yolk antibodies against F18ab fimbriae of Escherichia coli inhibit shedding ofFIS positive E. coli by experimentally infected pigs. Vet Microbiol. 1997 Mar;54(3-4):329-41.
Yokoyama H, Hashi T, Umeda K. et al. Effect of oral egg antibody in experimental F18+
Escherichia coli infection in weaned pigs. J Vet Med Sci. 1997 Oct;59(10): 917-21.
Sarker SA, Casswall TH. Mahalanabis D, et al. Successful treatment of rotavirus diarrhea in children with immunoglobulin from immunized bovine colostrum. Pediatr Infect Dis J. 1998 Dec; 17(12): 1149-54.
Kollberg H, Carlander D. Olesen H, Wejaker PE, Johannesson M, Larsson A. Oral administration of specific yolk antibodies (IgY) may prevent: Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr Pulmonol. 2003 Jim; 35(6): 433-40.
Xie MQ, Meng YX, Li ZH, et al. Effect of specific immunoglobulin Y in the treatment of acute and chronic pharyngitis. Zhonghua Er Bi Yan Hou Ke Za Zhi. 2004 Feb;39(2): 112-5.
Watson RR, Zibadi S, Vazquez R, Larson D. Nutritional regulation of iinm unosenescence for heart health. JNutr Biochem. 2005 Feb;16(2):85-7.
Petermans J. Physical exercise in the aged. Rev Med Liege. 2001 Apr; 56(4): 223-7.
Available at
http://www. hyper immimeegg.org/studies/Scheett J3olandJRi\wa^4naobolicMediators.pdf.
Accessed Janaury 31, 2011.
Available at: http://www.hyperimmuneegg.org/NSCA.pdf Accessed Janaury 31, 2011.
Available at:http://www.hyperimmuneegg. org/Suhmax.pdf. Accessed January 31, 2011.
Desai S, Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep. 2010 Feb; 7(1): 4-10.
Kizito FB. Improvements in Quality of Life for HIV/ AIDS Patients Using Hyperimmune egg
(Immune 26™) The TASO Study. 3rd International AIDS Society Conference on HIV
Pathogenesis and Treatment. 2005. bstract No. MoPell.2C43.
Nio Y, Tobe T. Immunity of gut-associated lymphoid tissue and the role of the oral immunotherapy in multi-disciplinary treatment of the digestive organ cancer. Nippon Geka Gakkai Zasshi. 1989 Sep;90(9): 1436-8.
Bisht M, Bist SS, Dhasmana DC. Biological response modifiers: current use and future prospects in cancer therapy. Indian J Cancer. 2010 Oct-Dec:47(4):443-51.
Johansson JE, Ehnan T. Gut mucosa barrier preservation by orally administered IgA-IgG to patients undergoing bone marrow transplantation: a randomised pilot study. Bone Marrow Transplant. 1999 Jul;24( l):35-9.
Tollemar J, Gross N, Dolgiras N. Jarstrand C, Ringden O, Hammarstrom. L. Fungal prophylaxis by reduction offiingal colonization by oral administration of bovine anti-Candida antibodies in bone marrow transplant recipients. Bone Marrow Transplant. 1999 Feb:23(3):283-90.
Deborah B. WhitmThe Immunology of Ageing (Updated March 1999) Power Qest. www.csa.com Sonya Vasto and Calogero Caruso. Immunity and Ageing (I&A 10th Aniversery). Looking for an antibody against the mentioned targets? (2004)
Patents for poultry immunoglobulins (Gallus domesticus)
Nojiri et al.
5976519 Yolk antibody-containing hair care product 5814477 Recombinant clostridial toxin protein Williams et al. Lyman et al.
5728813 Antibodies directed against elk ligand
5601823 Avian antitoxins to Clostridium difficile toxin A Williams et al.
Oral administration of chicken yolk immunoglobulins to
5585098 lower somatic cell count in the milk of lactating ruminants Coleman
Lee et al.
5367054 Large-scale purification of egg immunoglobulin
Carroll
5340923 Methods for making and purifying antivenoms
4550019 Manufacture and use of fowl egg antibodies Poison
BRIEF DESCRIPTION OF INVENTION
Short description of technical solutions
Studies during 201 1-2014 were conducted to obtain an identified hyperimmune egg: hyperimmune egg PC2, containing antibodies for 10-30 pathogenic agents and/or toxic substances. This whole egg can be consumed raw, boiled at 65°C for 25 minutes, boiled at 100°C for 4.5 minutes. Under these conditions, the specific activities of all immunoglobulins are maintained. The hyperimmune egg PC2 can be preserved by drying using low temperature atomization or freeze-drying. The powder can be consumed as such or in mixture with cacao, water-dissolved vitamins, mineral water, soda or milk.
The immunization consists of the inoculation of minimum 10 bacterial antigens or mixture of 10-30 bacterial, viral and micotic antigens, dried by freeze-drying and mixed with an adjuvant QS21. This technology described in this patent is easy to use, and specific IgY can be sold at accessible price and exploited in the medical units of Romania.
This invention was to produce a hyperimmune egg which contains a group of 10-30 IgY of the yolk, consisting of the following steps:
(a) preparation of a complex antigen using antibiotic-resistant bacterial strains isolated from patients from Romania. The antigen is a mixture of antibiotic-resistant strains from a single species of bacteria or an antigen prepared from a mixture of various species of strains from various species of bacteria, with viral and micotic antigens;
(b) mixture of the antigen with adjuvant QS21 ;
(c) immunization of poultry with the antigen prepared as per section (a) and (b) generating specific antibodies in the chickens, which are then transferred and built up in the egg yolk;
(d) hyperimmune egg PC2 is used in the feed of over 65 years old people or as per recommendations in immunosuppressive patients, with oral, digestive diseases or mucosal, tissue or organ impairments.
BRIEF DESCRIPTION OF PROCEDURES
The objectives of this patent are revealed by the description below:
Annex # 1. The hyperimmune egg PC2 is prepared accordingly:
(a) IgY-specific identified by ELISA using IgG anti rabbit IgY (photo);
(b) IgY-specific quantitatively determined by ELISA (photo)
(c) IgY-specific qualitatively determined by ELISA (photo)
DETAILED DESCRIPTION OF INVENTION
According to this invention, the preparation of hyperimmune egg PC2 consists of various stages: preparation of antigen (1), immunization of conventional or SPF laying chickens (2) qualitative and quantitative antibody assessment (3).
Preparation of antigen
According to this invention, identified and multiplied antibiotic-resistant bacterial strains were isolated from patients. The bacterial cells washed 3 times in phosphate buffer (PBS) and centrifuged at 4000 rpm at 20°C, 15 minutes are freeze-dried in 10 ml vials, 4 ml bacterial suspension in each vial. After freeze-drying, the vials are stored at -20°C. 50 mg bacteria are re- suspended in phosphate buffer (PBS) at optical density OD6oo of 1.00 and mixed with 45μ1 adjuvant QS21. Viral antigens are obtained by cell culture replication of viruses and their inactivation with beta-propiolactone. After cultivation on selective media, fungi are inactivated for 60 minutes at 80°C.
1. Immunization of conventional or SPF laying chickens
The antigen is administered by intramuscular inoculation of 0.5 ml in four distinct sites on the chest muscles of conventional or SPF laying chickens. The antigen is inoculated three times every 14 days. The presence of specific antibodies in blood and eggs is tested after the second administration, by ELISA. Eggs are harvested 14 days after the third antigen inoculation, when antibody titer in serum and yolk is high. The antibody titer is assessed on regular basis from the eggs of chickens immunized with the target antigen.
The immunization of laying chickens with a target antigen is a well known technique. This invention can undertake any method of chicken immunization which consists of the administration of the target antigen by any route: subcutaneous, intracutaneous, intramuscular, intravenous. The control methods are detailed in the invention patent no. A/00156 from 25.02.2014
Adjuvant QS21 was used for this invention. Other types of adjuvants can also be used such as complete or incomplete Freund adjuvant or a mixture of them.
Using antigen QS21 mixed with the target antigen enhances the immune response, induces no local reactions and has been demonstrated to be efficient for the production and maintenance of a high titer for a long period of time, 12 months; adjuvant QS21 is important for the preparation of specific antibodies.
Hyperimmune egg PC2 from this invention is used for the preventive or curative treatment of bacterial, viral, micotic, yeast infections, after administration per os against digestive, pulmonary diseases, viral or other infections in the human body.
RECOMMENDED METHODS OF USING THIS INVENTION
The examples below are for illustration only and have no intention of restricting the purpose of this invention.
Example 1
(a) . Immunize each group of chickens with a set of 10-30 bacterial, viral or micotic antigens.
The bacterial and micotic strains can be isolated from patients from the hospitals of Romania. Some viral or micotic strains are represented by a mixture of strains isolated from patients from the hospitals of Romania and certified strains. This set of microorganisms consist of: Shigella dysenteriae, Staphylococcus epidermidis, Staphilococus simulans, Staphilococus aureus, Escherichia coli, Salmonella enteritidis and typhimurium, Pseudomonas aeruginosa, Klebsiella pneumoniae, Haemophilis influenzae, Stereptococus (6 species), Acinetobacter Baumani, Herpes simplex, Clostridium difficile (spores, vegetative form and exotoxins A and B).
(b) . Store each strain at -85°C as original product. Grow bacteria for antigen preparation in the recommended culture medium;
(c) . From the 24 hours bacterial culture, prepare a bacterial sediment equal to 2xl 010CFU, by centrifugation for 15 minutes at 4000 rpm at +20°C;
(d) . Re-suspend the obtained pellet in PBS at the initial volume and freeze-dry 2 ml in 4 ml vials. After freeze-drying, store the bacterial culture at -20°C;
(e) . Re-suspend the sediment obtained as per section c) at the initial volume in PBS with 0.4% formalin and incubate overnight at +37°C. Remove formalin by centrifugation for 15 minutes at 4000 rpm at +20°C. Re-suspend the inactivated bacteria in PBS and freeze-dry. After freeze-drying, store the vials at -20°C;
(f) . Prepare the antigen using 500 μg inactivated cells/ml or 3-4.5μg protein/ml reconstituted in 0.5 ml PBS and mix with 0.5 ml adjuvant QS21 . For chicken immunization, dilute equal parts of the mixture and 5% Tween 20 emulsifier;
(g) . The antigen is a mixture of strains from the same species of bacteria or a mixture of distinct species of bacterial strains;
(h) . Prepare the viral antigens from cell cultures with beta-propiolactone inactivated virus, purified by filtration through Millipore 0.45μηι filters.
(i). Prepare fungi antigens from the fungi cultures in selective media inactivated for 160 minutes at 80°.
(j). 140-180 days old, clinically healthy, conventional or SPF laying chickens are industrially reared, fed with Leghorn or Rhode Island Red laying chicken feed and with automatic watering systems.
(k). Inoculate the chickens intramuscularly in four distinct sites with 2 ml of target antigen;
(I). After the first administration, inoculate chickens twice with the same antigen, by the same administration route, at 14 days interval;
(m). Take blood samples during the second and third administration and perform the immune response control;
(n). Treat the blood samples taken from chickens after the second and third administration of antigen in order to express the serum extracted from the clot and store at +4°C or -20°C.
(o). Assess the immune response by qualitative and quantitative ELISA;
(p). Chickens with positive response to the target antigen are approved for hyperimmune egg PC2 production.
(q). The best time for egg harvesting is when 100-200 mg of IgY and 10-20 mg IgY specific are extracted from the yolk.
Example 2
IgY extraction
(a) . Separate the egg white from the yolk and extract after tearing the vitelline membrane from the eggs of immunized chickens 14 days after the last administration of target antigen.
(b) . Measure the volume of yolk and then mix with distilled water at +4°C, pH 4-7 in 1 :7 -1 :10 ratio and stir with a turmix for 5 minutes at room temperature.
(c) . Adjust pH at 4-and add Thimerosal 0.01%
(d) . Freeze the mixture at -20 -40°C directly or gradually, one degree per minute using liquid nitrogen.
(e) . After freezing the entire mixture, thaw at +20°C.
(f) . After separating the liquid and semisolid phases extract the aqueous phase;
(g) . Process IgY extracted in aqueous phase by filtration at 20°C using filters which allow the passing of proteins weighing less than 20kDa to retain water-insoluble biomolecules, most lipids and yolk granules.
(h) . Store IgY at +4°C for routine quantitative and qualitative determinations.
Perform quantitative and qualitative determinations using:
qualitative ELIS A;
> quantitative ELISA;
Example 3
Hyperimmune egg PC2 filling
After determining the specific bacterial growth inhibition activity, hyperimmune eggs are filled by:
(a) . Take the eggs from the collecting conveyor and transport them in the frigorific room at
+4- 8°C;
(b) . Select and remove broken and dirty eggs;
(c) . Mark each egg with the date of manufacture and potency;
(d) . Automatically distribute in egg cartons with 6, 12 and 36 eggs;
(e) . On each carton put labels with information on the hyperimmune egg PC2;
(f) . State the storage method, use and expiry date on the label;
(g) . Store and transport the hyperimmune eggs PC2 packed in cartons at +4 - 8°C;
(h) . Store hyperimmune eggs PC2 until use at +4-8°C.
Example 4
Preparation of the whole granulated hyperimmune egg PC2 integral by atomization
Wash, break and separate the hyperimmune egg PC2 from its shell by hand or using an automatic device. Mix the contents of the egg into a special mixing machine and transfer at +10C° into a low temperature drying device (+65°C) and then into a stainless steel container and then from a dosage device fill the whole granulated egg into vials of 350g, 170g or aluminum foil sealed vials. Pack the labeled vials into individual and collective boxes.
The individual boxes with 12 and 6 g are distributed in plastic heat-closed bags. The final packaging consists of carton boxes of 50 bags per box.
The granulated hyperimmune egg PC2 can be stored at +20-22°C for one year and at +4- 8°C for at least 2 years.
Example 5
Preparation of the whole granulated hyperimmune egg PC2 by vacuum drying (freeze-drying)
Freeze-dry the whole egg mixture according to Ex. 4 using an intensive vacuum drying program, at an eutectic point of -30-56°C, with a special evaporation program at -4°C and final temperature of +30°C.
After freeze-drying fill the granulated hyperimmune egg PC2 according to Ex. 4.
Example 6
Final control of IgY
The below described methods of control are used for the final formulation of hyperimmune egg PC2, for oral administration:
> Microbiological sterility: food standard.
(EC) Regulation no. 2160/2003 of the European Parliament and Council regarding the control of Salmonella infections and other specific food-borne zoonotic agents.
(EC) Regulation no. 852/2004 on food sanitation foresees that eggs are basic food products. All EC legislation provisions on sanitation.
> Determination of specific IgY activity by ELISA;
> Determination of IgY content by ELISA;
Only the control-appropriate batches of specific IgY, according to e.g. 6.a are approved for human consumption.
Example 7
A. Quantitative determination of IgY by ELISA
ELISA is "in house" prepared for each and every assay.
ELISA can detect very high dilutions of immunoglobulins. The minimum detected amount of OTF-M is 10 nanograms in the tested material. Due to the specificity and reproducibility of
immunoenzymatic reaction, ELISA is used in the manufacturing process of IgY, on production stages and during qualitative and quantitative control.
(a) . Perform the ELISA to be used in the quantitative control of IgY by comparing with an international IgY standard (USA) or with an IgY substandard prepared at Romvac;
(b) . Cover the wells with 150μ1 anti-avian rabbit serum IgG at 3.75 μπι/ml concentration in carbonate-bicarbonate buffer;
(c) . Incubate the 96-ELISA well plates for 90 minutes at +37°C;
(d) . Wash four times in 300 μΐ PBT-Tween using an automatic plate washer;
(e) . Add 200 μΐ of 1% BSA in PBS-Tween in each well and incubate for 45 minutes at +37°C;
(f) . Wash the reaction plate four times in PBS-Tween as per section (d);
(g) . Add in triplicate 150 μΐ specific IgY or IgY SPF (25, 12.5, 6.25 μ%/πιΙ) in PBS;
(h) . Add in parallel in triplicate 150 μΐ standard IgY SIGMA ((25, 12.5, 6.25 μg/ml);
(i) . Incubate plates at +37°C for 90 minutes;
(j). Wash plates four times in PBS-Tween;
(k). Add 150 μΐ IgG anti IgY conjugated with peroxidase to 1 :5000 dilution;
(1). Add 150 μΐ TMB and incubate for 5-15 minutes at room temperature in the dark
(m). Freeze the reaction with 150μ1 HC1;
(n). Read the reaction under D045o filter spectrophotometer;
(0) . Perform comparative standard curves and consider the highest positive dilution to 0.200
OD.
B. Quantitative determination of IgY by direct ELISA
(a) . Cover the plate overnight at +4°C or for 2 hours at room temperature with IgY to be tested and standard IgY each in three replicates, in binary dilutions starting with 1 : 1000 dilution in carbonate-bicarbonate solution;
(b) . Keep wells A l and HI as IgY controls;
(c) . Wash 3 times with wash solution;
(d) . Add 100 μΐ avian anti- IgY 1 :5000 diluted conjugate;
(e) . Incubate the plate for 2 hours at +37°C;
(f) . Wash 4 times with wash solution;
(h). Add 100 μΐ TMB and leave at room temperature for 5-15 min;
(1) . Add 100 μΐ stop solution;
(j). Read the reaction absorbance under 450 nm filter spectrophotometer;
(k). Assay the reaction by blank wells control where D045o should be maximum 0.060. The reaction is not valid if other values are obtained;
(1). The dilution for which D045o is 0.200 or higher is considered positive reaction for IgY presence;
If the reaction plate is valid, compare positive reactions from test IgY with the international standard IgY;
Perform the g/ml IgY content in comparison with reference IgY taking into account that ELISA detects minimum 10 ng/ml and it is performed in comparison with standard IgY.
Example 8
C. Determination of specific IgY content by ELISA
The specific IgY activity is determined by a quantitative method against the antigen represented by the whole bacterial cells inactivated and freeze-dried as per section (1.). The reaction plate is covered with an antigen and specific IgY is tested in successive binary dilutions starting from 1 :1000 dilution in triplicate. The highest positive dilution is when the reaction is equal or higher than 0.200 OD or the numerical value for the dilution higher than 0.200 OD. The positive reaction to this dilution is given by 5-lOng of specific IgY per well, per 150μ1.
Cover an ELISA plate with 150 μΐ from the suspension of bacteria freeze-dried at 1.67- 1.70 μg cells per ml or 10 μg bacterial protein per ml in carbonate-bicarbonate buffer (0.05 M, pH 9.6);
Store the covered plate for 12 hours (overnight) at +4°C;
After removal of the liqu id, wash the plate 3 times in PBS-Tween 20 (2%) wash solution;
Stop the reaction with fixation buffer, 300 μΐ/ well and incubate the plate for 30 minutes at room temperature;
Remove the stop liquid;
Dry the plate for 30 minutes in desiccator;
Distribute in each well 100 μΐ from the IgY suspension diluted 1 : 1000 in binary dilutions up to 1 :24 as per the plate configuration. Test IgY to be assessed in triplicate;
Keep wells Al and HI as antigen controls, wells Bl, CI and Dl as negative reaction controls using IgY-SPF and wells El, Fl and Gl as positive reaction controls using reference specific IgY of Romvac;
Incubate the plate for 2 hours at +37°C;
Wash 3 times in wash solution;
(k). Add 100 μΐ of 1 :5000 diluted anti-avian conjugate using the dilution buffer as diluent;
(1). Incubate the plate for 2 hours at +37°C;
(m). Wash the plate 4 times in wash solution;
(n). Add 100 μΐ TMB and leave at room temperature for 5-15 min.
(o). Add 100 μΐ stop solution;
(p). Read the reaction under 450 nm absorbance spectrophotometer;
(r). The reaction is valid when the reaction in the control blank wells Al and HI reveal values lower than 0.060 DO, when the reaction in wells Bl, CI and Dl of control IgY-SPF (negative) reveal values of 0.060-0.090 OD, and positive control wells El, Fl, Gl reveal values of 1.400-1.800 OD.
Claims
1. The method of manufacture of the hyperimmune egg PC2 consists of the immunization of laying chickens with an antigenic mass containing antigens from human-pathogenic bacteria, viruses and fungi.
2. Claims for the method in section 1 refer to the fact that the antigen is a mixture of antibiotic-resistant strains from the same species of bacteria.
3. Claims for the method in section 1 refer to the fact that the antigen is a mixture of bacterial strains from various antibiotic-resistant species of bacteria.
4. Claims for the method in section 1 refer to the fact that the antigen contains a mixture of inactivated bacteria, viruses and fungi mixed with an adjuvant QS21 which is very well tolerated by chickens inoculated intramuscularly.
5. Claims for the method in section 1 refer to the fact that the antigen contains a mixture of inactivated bacteria, viruses and fungi mixed with an adjuvant QS21, which provides an immunological stimulus which generates a uniform immune response in the organism of chickens for each antigen.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15753214.4A EP3212664A1 (en) | 2014-10-29 | 2015-07-21 | Manufacture and use of hyperimmune egg pc2 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ROA/2014/00810 | 2014-10-29 | ||
ROA201400810A RO130213A8 (en) | 2014-10-29 | 2014-10-29 | Production and use of hyperimmune egg - pc2 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016114677A1 true WO2016114677A1 (en) | 2016-07-21 |
Family
ID=53188723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RO2015/000019 WO2016114677A1 (en) | 2014-10-29 | 2015-07-21 | Manufacture and use of hyperimmune egg pc2 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3212664A1 (en) |
MA (1) | MA40520A (en) |
RO (1) | RO130213A8 (en) |
WO (1) | WO2016114677A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108992669A (en) * | 2018-08-27 | 2018-12-14 | 广州汇高生物科技有限公司 | Composite yolk antibody composition, aerosol inhalation solution agent and the preparation process and application for preventing and treating respiratory tract infection |
WO2019039948A1 (en) * | 2017-06-06 | 2019-02-28 | Fântână, Raul Sorin | Composition, preparation method and evaluation of a complex immunogen named i-spga for production of immunological active proteins (iap) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RO130965A8 (en) * | 2015-10-16 | 2017-06-30 | Romvac Company S.A. | Production and use of customized hyperimmune egg () in psoriasis treatment |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000027410A2 (en) * | 1998-11-05 | 2000-05-18 | Dcv, Inc. | Composition and method for increasing weight gain and feed efficiency |
WO2000043020A1 (en) * | 1999-01-19 | 2000-07-27 | Dcv, Inc. | Egg anti-inflammatory composition and method of treating and preventing inflammation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RO129645B1 (en) * | 2014-02-25 | 2022-05-30 | Romvac Company S.A. | Process for obtaining and using hen immunoglobulins (igy) |
-
2014
- 2014-10-29 RO ROA201400810A patent/RO130213A8/en unknown
-
2015
- 2015-07-21 MA MA040520A patent/MA40520A/en unknown
- 2015-07-21 WO PCT/RO2015/000019 patent/WO2016114677A1/en active Application Filing
- 2015-07-21 EP EP15753214.4A patent/EP3212664A1/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000027410A2 (en) * | 1998-11-05 | 2000-05-18 | Dcv, Inc. | Composition and method for increasing weight gain and feed efficiency |
WO2000043020A1 (en) * | 1999-01-19 | 2000-07-27 | Dcv, Inc. | Egg anti-inflammatory composition and method of treating and preventing inflammation |
Non-Patent Citations (3)
Title |
---|
KOLLBERG HANS ET AL: "Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study", PEDIATRIC PULMONOLOGY, JOHN WILEY, NEW YORK, NY, US, vol. 35, no. 6, 1 June 2003 (2003-06-01), pages 433 - 440, XP002524346, ISSN: 8755-6863, [retrieved on 20030508], DOI: 10.1002/PPUL.10290 * |
MORNINGSTAR ET AL: "Hyperimmune egg powder for the treatment of irritable bowel syndrome: A case series", 20041201, vol. 3, no. 1, 1 December 2004 (2004-12-01), pages 12 - 14, XP022378264 * |
YOKOYAMA H ET AL: "Passive protective effect of chicken egg yolk immunoglobulins against experimental enterotoxigenic Escherichia coli infection in neonatal piglets", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 60, no. 3, 1 March 1992 (1992-03-01), pages 998 - 1007, XP002109373, ISSN: 0019-9567 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019039948A1 (en) * | 2017-06-06 | 2019-02-28 | Fântână, Raul Sorin | Composition, preparation method and evaluation of a complex immunogen named i-spga for production of immunological active proteins (iap) |
US11458196B2 (en) | 2017-06-06 | 2022-10-04 | Raul Sorin Fântâna | Composition, preparation method and evaluation of a complex immunogen named I-SPGA for production of immunological active proteins (IAP) |
CN108992669A (en) * | 2018-08-27 | 2018-12-14 | 广州汇高生物科技有限公司 | Composite yolk antibody composition, aerosol inhalation solution agent and the preparation process and application for preventing and treating respiratory tract infection |
Also Published As
Publication number | Publication date |
---|---|
RO130213A8 (en) | 2017-06-30 |
MA40520A (en) | 2016-07-21 |
EP3212664A1 (en) | 2017-09-06 |
RO130213A0 (en) | 2015-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2340492T3 (en) | IMMUNE MODULATION METHODS IN ANIMALS. | |
EP0918528B1 (en) | Use of hyperimmunized milk and/or egg for treating gastrointestinal damage | |
CN103533958B (en) | Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications | |
Tsubokura et al. | Oral administration of antibodies as prophylaxis and therapy in Campylobacter jejuni‐infected chickens | |
Wong et al. | Bovine colostrum enhances natural killer cell activity and immune response in a mouse model of influenza infection and mediates intestinal immunity through toll-like receptors 2 and 4 | |
Wiedemann et al. | Chicken egg antibodies for prophylaxis and therapy of infectious intestinal diseases: V. in vivo studies on protective effects against Escherichia coli diarrhea in pigs | |
US20200108144A1 (en) | Composition and Methods for Treating Acute Diarrhea and Enteric | |
JPH0160455B2 (en) | ||
EP3212664A1 (en) | Manufacture and use of hyperimmune egg pc2 | |
Isfahani et al. | The effect of capsulated and noncapsulated egg-yolk–specific antibody to reduce colonization in the intestine of Salmonella enterica ssp. enterica serovar Infantis–challenged broiler chickens | |
CN102791732A (en) | Milk derived antigen specific antibodies for inducing an adaptive immune response, methods of preparation and uses thereof | |
PL214224B1 (en) | Methods and compositions for modulating the immune system of animals | |
US10632158B2 (en) | Use of a hyperimmune egg product to prevent and treat dysbiosis | |
WO1999002188A1 (en) | Hen egg yolk antibodies to clostridium difficile antigens and use in therapy for pseudomembranous colitis | |
JP2007082469A (en) | Oral-care food and drink | |
US6803035B2 (en) | Anti-diarrheal and method for using the same | |
EP1589995B1 (en) | Use of avian antibodies | |
JPH1180197A (en) | Preventive and therapeutic agent against helicobacter pylori and relating infections | |
US10478493B2 (en) | Method of treating protozoal gastrointestinal disorders in immunocompromised patients | |
US10010531B2 (en) | Methods and compositions for treating clostridium difficile associated disease | |
RU2262350C2 (en) | Vaccine for prophylaxis and immunotherapy of human and animal diseases caused by pathogenic and opportunistic gram-negative microorganisms of intestine group and their exotoxins and method for its preparing (variants), immunoglobulin preparation (variant) and method for its preparing, immunobiological preparation polycomponent vaccine | |
JP3597784B2 (en) | Peptic ulcer inhibitory composition and food and drink containing it | |
US20210252149A1 (en) | Composition and Methods for Treating Infectious Agents Using Pathogen-specific Antibodies | |
JP2001502309A (en) | Use of immunoglobulin preparations for the manufacture of an orally administered drug for preventing hemolytic uremic syndrome | |
WO1998055143A1 (en) | Lipid-reduced oral formulation for egg yolk-derived therapeutic protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15753214 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2015753214 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015753214 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |